Vanda Pharmaceuticals Inc
F:VM4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vanda Pharmaceuticals Inc
F:VM4
|
US |
|
Guardant Health Inc
NASDAQ:GH
|
US |
|
N
|
Nano One Materials Corp
SWB:LBMB
|
CA |
|
B
|
BHP Group Ltd
JSE:BHG
|
AU |
|
A
|
American Homes 4 Rent
F:A4XA
|
US |
|
Aleatica SAB de CV
BMV:ALEATIC
|
MX |
|
EverQuote Inc
NASDAQ:EVER
|
US |
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
AVG Logistics Ltd
NSE:AVG
|
IN |
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals is a small specialty drug company that develops and sells prescription medicines for the brain and sleep. Its best-known products treat sleep-wake disorders and certain psychiatric conditions, including drugs doctors prescribe for non-24-hour sleep disorder and schizophrenia. The company does not sell consumer health products; it focuses on medicines that are prescribed by physicians and dispensed through pharmacies. Vanda makes money mainly by selling its branded drugs to patients through the normal prescription channel, with insurers and pharmacy benefit managers often involved in payment. It may also earn licensing or royalty income from products or drug rights it has partnered or out-licensed. That means its business depends on a limited number of approved medicines rather than a large catalog of drugs. What makes Vanda different is that it sits in a narrow part of the pharmaceutical industry: specialty neuroscience and sleep medicine. Instead of trying to be a broad drugmaker, it focuses on a few hard-to-treat conditions where branded prescriptions and specialist doctors matter. This gives the company a more concentrated, high-risk business model, but also one tied closely to specific medical needs rather than mass-market sales.
Vanda Pharmaceuticals is a small specialty drug company that develops and sells prescription medicines for the brain and sleep. Its best-known products treat sleep-wake disorders and certain psychiatric conditions, including drugs doctors prescribe for non-24-hour sleep disorder and schizophrenia. The company does not sell consumer health products; it focuses on medicines that are prescribed by physicians and dispensed through pharmacies.
Vanda makes money mainly by selling its branded drugs to patients through the normal prescription channel, with insurers and pharmacy benefit managers often involved in payment. It may also earn licensing or royalty income from products or drug rights it has partnered or out-licensed. That means its business depends on a limited number of approved medicines rather than a large catalog of drugs.
What makes Vanda different is that it sits in a narrow part of the pharmaceutical industry: specialty neuroscience and sleep medicine. Instead of trying to be a broad drugmaker, it focuses on a few hard-to-treat conditions where branded prescriptions and specialist doctors matter. This gives the company a more concentrated, high-risk business model, but also one tied closely to specific medical needs rather than mass-market sales.
Revenue: First-quarter revenue was $51.7 million, up 3% year over year but down 10% sequentially, with Fanapt growth partly offset by lower HETLIOZ sales from generic competition.
Guidance: Vanda raised full-year 2026 revenue guidance to $240 million to $290 million, now including $10 million to $30 million from newly launched NEREUS.
Fanapt: Fanapt remained the main growth driver, with sales up 26% year over year, TRx up 32%, and NBRx up 76%; weekly TRx hit an 11-year high in April.
Launches: NEREUS launched nationwide through a direct-to-consumer platform, while BYSANTI received FDA approval and is still expected to be available in the back half of 2026.
Pipeline: Management highlighted multiple late-stage readouts in 2026 and early 2027, including NEREUS in GLP-1 patients, VQW-765 in social anxiety disorder, and BYSANTI in major depressive disorder.
Cash burn: Cash ended the quarter at $202.3 million, down $61.5 million from year-end 2025, and management said 2026 cash burn is likely to be greater than in 2025.
